secwatch.observer — SEC 8-K summary
======================================

Issuer:     RECURSION PHARMACEUTICALS, INC. (RXRX)
CIK:        0001601830
Form:       8-K
Filed at:   2023-02-27T23:59:59+00:00
Accession:  0001601830-23-000009
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Recursion reports FY2022 net loss $239.5M; cash $549.9M; pipeline advances
--------------------------------------------------------------------------

- Net loss of $239.5M for FY2022, up from $186.5M in FY2021; Q4 net loss $57.5M.
- Revenue of $39.8M (FY2022) vs $10.2M prior year, driven by Roche-Genentech collaboration.
- Cash, cash equivalents and investments $549.9M as of Dec 31, 2022, up from $516.6M.
- Initiated five clinical trials in 2022; expects top-line data for REC-994 (CCM) in 2H 2024 and REC-3964 (C. diff) safety/PK data in 2H 2023.
- Released RxRx3 open-source cellular imaging dataset and MolRec application in January 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1601830/000160183023000009/0001601830-23-000009-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1601830/000160183023000009/rxrx-20230227.htm
  HTML page:      https://secwatch.observer/filing/0001601830-23-000009

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer